Leerink Partners Resumes Zogenix, Inc. (ZGNX) at Outperform
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Leerink Partners resumes coverage on Zogenix, Inc. (NASDAQ: ZGNX) with a Outperform rating and a price target of $17.00.
Analyst Paul Matteis commented, "At a ~$315MM market cap, we see a favorable risk/reward for ZGNX shares ahead of multiple data readouts for lead product ZX008 across orphan epilepsies. Although results generated to date are single arm and from a single center - and thus should be interpreted with some caution - we are encouraged that the 75%+ seizure reductions of observed on '008 in highly refractory populations with Dravet Syndrome are orders of magnitude larger than the placebo rate observed in recent GWPH (OP) pivotal trials. Preliminary data in an LGS pilot trial are expected at AES in December, while results from the ph3 ZX008 are expected in 2Q17."
Shares of Zogenix, Inc. closed at $11.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Under Armour, Inc. (UA) to Neutral Citing Structural Margin Challenges
- RBC Capital Raises Price Target on Akamai Technologies (AKAM) to $67 Following Solid 3Q
- Credit Suisse Downgrades Chipotle Mexican Grill (CMG) to Neutral; 'New Normal'
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!